Fierce Healthcare August 9, 2024
Wealthy Democratic donors, seemingly reinvigorated by the new-look presidential race, are publicly expressing contempt for Federal Trade Commission (FTC) Chair Lina Khan, one of the nation’s key antitrust watchdogs.
The goal, it appears, is to flex financial power and persuade Vice President Kamala Harris to remove Khan from her post if elected to office and to move Harris away from a Biden agenda they see as sour toward business-friendly deals.
Ousting Khan could have significant implications on the future of antitrust. In healthcare, that could mean a strategic shift in how pharmacy benefit manager (PBM) investigations are approached by the country’s premier competition protection agency.
It is also sparking a contentious, public debate on Khan’s effectiveness as chair.
“It’s been...
Today's Sponsors
Today's Sponsor